Preventive effect of agaro-oligosaccharides on non-steroidal anti-inflammatory drug-induced small intestinal injury in mice

J Gastroenterol Hepatol. 2014 Feb;29(2):310-7. doi: 10.1111/jgh.12373.

Abstract

Background and aim: Non-steroidal anti-inflammatory drugs (NSAIDs), which are commonly used in clinical medicine, cause erosion, ulcers, and bleeding in the gastrointestinal tract. No effective agent for the prevention and treatment of small intestinal injury by NSAIDs has been established. This study investigates the effects of agaro-oligosaccharides (AGOs) on NSAID-induced small intestinal injury in mice.

Methods: Mice were treated with indomethacin, an NSAID, to induce intestinal injury. The respective degrees of mucosal injury of mice that received AGO and control mice were compared. Heme oxygenase-1 (HO-1) expression using quantitative real-time polymerase chain reaction (qRT-PCR), Western blotting, and immunohistochemistry were measured. The expression of keratinocyte chemoattractant (KC) was measured using qRT-PCR and enzyme-linked immunosorbent assay.

Results: AGO administration induced HO-1 expression in mouse small intestinal mucosa. Induction was observed mainly in F4/80 positive macrophages. The increased ulcers score, myeloperoxidase activity, and KC expression by indomethacin were inhibited by AGO administration. Conversely, HO inhibitor cancelled AGO-mediated prevention of intestinal injury. In mouse peritoneal macrophages, AGOs enhanced HO-1 expression and suppressed lipopolysaccharide-induced KC expression. Furthermore, AGOs enhanced the expressions of alternatively activated macrophage markers arginase-1, mannose receptor-1, and chitinase 3-like 3.

Conclusions: Results suggest that oral administration of AGOs prevents NSAID-induced intestinal injury.

Keywords: M2 macrophage; heme oxygenase; indomethacin; interleukin-8; keratinocyte chemoattractant.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
  • Arginase / metabolism
  • Chemotactic Factors / metabolism
  • Heme Oxygenase-1 / metabolism
  • Indomethacin / adverse effects*
  • Intestinal Diseases / chemically induced*
  • Intestinal Diseases / metabolism
  • Intestinal Diseases / prevention & control*
  • Intestinal Mucosa* / enzymology
  • Intestinal Mucosa* / metabolism
  • Intestine, Small* / metabolism
  • Keratinocytes
  • Lectins / metabolism
  • Macrophages, Peritoneal / metabolism
  • Male
  • Membrane Glycoproteins / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Oligosaccharides / administration & dosage*
  • Oligosaccharides / pharmacology*
  • Peroxidase / metabolism
  • Receptors, Cell Surface / metabolism
  • Receptors, Immunologic
  • beta-N-Acetylhexosaminidases / metabolism

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Chemotactic Factors
  • Lectins
  • MRC1 protein, mouse
  • Membrane Glycoproteins
  • Oligosaccharides
  • Receptors, Cell Surface
  • Receptors, Immunologic
  • Peroxidase
  • Heme Oxygenase-1
  • Chil3 protein, mouse
  • beta-N-Acetylhexosaminidases
  • Arg1 protein, mouse
  • Arginase
  • Indomethacin